GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other pharmaceutical ... due to advancements in therapeutic techniques, drugs, and medical technology.

“With this new agreement, we will apply GSK’s capabilities, partnerships, and intellectual property to CureVac’s technology, to deliver these promising vaccines at pace,” said the UK ...

In trading on Tuesday, shares of GSK plc (Symbol: GSK) crossed above their 200 day moving average of $38.45, changing hands as high as $39.19 per share. GSK plc shares are currently trading up ...

Zymeworks (ZYME) announced achievement of a $14M cash research milestone from GSK (GSK) associated with a clinical milestone. “In April 2016, ...

a GSK spokesperson said. “Our Cambridge Park Drive facility is home to cutting-edge technology platforms, including DNA encoded library technologies, respiratory and immunology research ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK ... that special with respect to other verticals, including technology and industrials, such that President Trump would ...

The company noted that it entered into platform technology transfer and license agreement with GSK for research, development and commercialization of upto six bispecific antibodies generated using ...

In April 2016, we entered into a platform technology transfer and license agreement with GSK to research, develop and commercialize up to six bispecific antibodies generated using our Azymetric™ ...

Hanon meanwhile is joined at Vicebio by two other ex-GSK staffers – Dr Giovanni Della Cioppa and Dr Jean Smal – who will serve as chief medical officer and chief technology officer ...